James Peyer: testing metabolic biology in humans
LinkedIn caption
🧬 James Peyer of Cambrian Bio, pictured in conversation at ARDD 2026. His conference presentation examined AMPK network activation as an approach to metabolic decline.
The official recap describes early human findings for ATX-304, including changes in resting metabolic rate and cardiometabolic measurements. These findings came from a small, early-stage study, and the presentation did not report human weight-loss results.
That distinction matters as the program moves toward further trials: promising biological signals need to be tested against meaningful clinical outcomes. A community moment alongside the work of translating aging biology into medicines.
📷 Donis Perkins and Alex Zhavoronkov
#ARDD2026 #DrugDiscovery
X caption
🧬 James Peyer at #ARDD2026. His ATX-304 presentation explored AMPK network activation, with early human metabolic findings and further trials ahead. Human weight-loss results were not reported.
📷 Donis Perkins and Alex Zhavoronkov
Photo: Donis Perkins and Alex Zhavoronkov
Copy and paste the caption manually, then attach the downloaded photo. Nothing is published automatically.
